353 related articles for article (PubMed ID: 36647827)
1. Impact of epigenetic reprogramming on antitumor immune responses in glioma.
McClellan BL; Haase S; Nunez FJ; Alghamri MS; Dabaja AA; Lowenstein PR; Castro MG
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647827
[TBL] [Abstract][Full Text] [Related]
2. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
3. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
[TBL] [Abstract][Full Text] [Related]
4. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Miller JJ; Shih HA; Andronesi OC; Cahill DP
Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of tumor-immune symbiosis in glioma.
Liu Y; Ali H; Khan F; Pang L; Chen P
Trends Mol Med; 2024 May; 30(5):429-442. PubMed ID: 38453529
[TBL] [Abstract][Full Text] [Related]
8. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
9. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
10. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
11. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
Yan D; Li W; Liu Q; Yang K
Front Immunol; 2022; 13():914618. PubMed ID: 35769466
[TBL] [Abstract][Full Text] [Related]
12. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
Picca A; Finocchiaro G
Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
14. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Lodi R; Brandes AA
Mol Diagn Ther; 2021 Jul; 25(4):457-473. PubMed ID: 34095989
[TBL] [Abstract][Full Text] [Related]
15. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Turcan S; Makarov V; Taranda J; Wang Y; Fabius AWM; Wu W; Zheng Y; El-Amine N; Haddock S; Nanjangud G; LeKaye HC; Brennan C; Cross J; Huse JT; Kelleher NL; Osten P; Thompson CB; Chan TA
Nat Genet; 2018 Jan; 50(1):62-72. PubMed ID: 29180699
[TBL] [Abstract][Full Text] [Related]
16. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.
Govindarajan V; Shah AH; Di L; Rivas S; Suter RK; Eichberg DG; Luther E; Lu V; Morell AA; Ivan ME; Komotar RJ; Ayad N; De La Fuente M
World Neurosurg; 2022 Jun; 162():47-56. PubMed ID: 35314408
[TBL] [Abstract][Full Text] [Related]
18. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
[TBL] [Abstract][Full Text] [Related]
19. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
20. New insights into the Immune TME of adult-type diffuse gliomas.
Richard Q; Laurenge A; Mallat M; Sanson M; Castro-Vega LJ
Curr Opin Neurol; 2022 Dec; 35(6):794-802. PubMed ID: 36226710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
